Navigation Links
Neurobiological Technologies, Inc. Reports Fourth Quarter and Fiscal Year-End Financial Results for 2007 Announces 1-for-7 Reverse Stock Split
Date:9/14/2007

ants totaled $980,000 for the year ended June 30, 2007 compared to zero in fiscal year 2006. In April 2007, the Company sold 3,043,478 shares of common stock and warrants and the Company recognized a change in the value of the warrants of $980,000 during the fourth quarter of fiscal year 2007 due to a decline in the Company's stock price during that time.

Bridge Financing

On September 12, 2007, the Company completed a $6.0 million debt and equity bridge financing under its effective shelf registration statement. In the financing, the Company issued $6.0 million in principal amount of 15% senior secured promissory notes due January 15, 2008 and 2,750,000 shares of common stock, which will be subject to certain trading restrictions until January 15, 2008. The Company expects to repay the indebtedness in October 2007 with proceeds from its planned registered public offering.

Reverse Stock Split

On September 12, 2007, the Company received stockholder approval for a reverse split of its outstanding common stock within a range of 1-for-5 to 1-for-7. On September 14, 2007, a committee of the Board approved the implementation of the reverse split at a ratio of 1-for-7. The reverse split will be come effective on Monday, September 17, 2007 and the Company's common stock will begin trading on the NASDAQ Capital Market on a post-split basis that day.

Upon effectiveness of the reverse split, every seven shares of common stock issued and outstanding will be automatically converted into one new share of common stock. Fractional shares that result from the split will not be issued and holders will be paid cash in lieu of fractional shares. The Company's common stock will trade under the symbol "NTIID" for 20 trading days to denote the reverse split. After that time, the symbol will revert to "NTII". Holders of record will receive instructions from American Stock Transfer & Trust Company, the Company's transfer agent, for how to surrender their pre-spl
'/>"/>

SOURCE Neurobiological Technologies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... (PRWEB) August 21, 2014 Ontotext ... today by Ontotext . Now the same ... analysis of structured and unstructured data is available to ... cost of enterprise technology. Organizations that do not have ... data management can use S4 since there is no ...
(Date:8/21/2014)... 2014 SoundConnect , a ... as one of the nation’s Fastest Growing Private ... the 2nd consecutive year. Inc. magazine today ranked ... 500|5000, an exclusive ranking of the nation's fastest-growing ... look at the most important segment of the ...
(Date:8/20/2014)... , Aug. 20, 2014 Clintrax ... services located in Raleigh, NC ... Evans as Vice President of Administration. ... will oversee all corporate processes, including their alignment ... Clintrax Global, Brad worked as an HR executive, ...
(Date:8/20/2014)... often have it that American Indians largely were wiped ... influenza and tuberculosis brought to the New World by ... 20 million people lived in the Americas shortly before ... killed by European diseases., But new research led by ... Johannes Krause of the University of Tubingen in Germany ...
Breaking Biology Technology:Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 2Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 3Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 4SoundConnect Returns on Inc. 5000 List of Fastest Growing Companies 2SoundConnect Returns on Inc. 5000 List of Fastest Growing Companies 3Clintrax Global, Inc. Announces Addition to Executive Team 2Unusual discovery leads to fascinating tuberculosis theory 2Unusual discovery leads to fascinating tuberculosis theory 3
... - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI , ... second quarter ended June 30, 2009. , "We were ... Medical Products business during the quarter, including continued acceleration ... said Dr. William Hunter, President and CEO of Angiotech. ...
... , , SEATTLE, Aug. ... reported recent achievements and financial results for the second quarter and ... "The second quarter of 2009 was a transforming quarter for the ... III data at the American Society of Clinical Oncology Annual Meeting ...
... , NEW YORK, Aug. 5 ... biopharmaceutical company focused on the acquisition, development and commercialization ... of life-threatening diseases, including renal disease and cancer (the ... ended June 30, 2009. , , ...
Cached Biology Technology:Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 2Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 3Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 4Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 5Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 6Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 7Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 8Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 9Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 10Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 11Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 12Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 13Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 14Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 15Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 16Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 17Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 18Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 19Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 20Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 21Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 22Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 23Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 24Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 25Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 26Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 27Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 28Cell Therapeutics Second Quarter Net Loss Decreases 54%; Pixantrone NDA Submitted to the FDA for Approval 2Cell Therapeutics Second Quarter Net Loss Decreases 54%; Pixantrone NDA Submitted to the FDA for Approval 3Cell Therapeutics Second Quarter Net Loss Decreases 54%; Pixantrone NDA Submitted to the FDA for Approval 4Cell Therapeutics Second Quarter Net Loss Decreases 54%; Pixantrone NDA Submitted to the FDA for Approval 5Cell Therapeutics Second Quarter Net Loss Decreases 54%; Pixantrone NDA Submitted to the FDA for Approval 6Cell Therapeutics Second Quarter Net Loss Decreases 54%; Pixantrone NDA Submitted to the FDA for Approval 7Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results 2Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results 3
(Date:8/20/2014)... approximately 3 million infants, a team of scientists across ... Massachusetts Medical School, have shown that newborn screening for ... public health newborn screening programs. Data from 11 newborn ... the Journal of the American Medical Association ... newborns is higher than previously thought and believed to ...
(Date:8/20/2014)... have suffered concussions ready to return to action? A ... school athletes who head back on the field with ... in their abilities to simultaneously walk and do simple ... in their balance and/or altered walking speed, was found ... had returned to activity in less than a month. ...
(Date:8/20/2014)... could one day be made out of cocoa, rice ... reporting. The novel process they developed and their results, ... and plastic waste problems, appear in the ACS journal ... and colleagues at the Italian Institute of Technology point ... its production reached 288 million tons worldwide, but its ...
Breaking Biology News(10 mins):Newborn screening expansion offers early diagnosis and treatment to infants with SCID 2Newborn screening expansion offers early diagnosis and treatment to infants with SCID 3Recovery reversal seen in Oregon study of returning concussed athletes 2Recovery reversal seen in Oregon study of returning concussed athletes 3
... the health of the world,s oceans down a rapid ... or perhaps ultimately reverse the catastrophic problems they are ... a professor of oceanography at Scripps Institution of Oceanography ... of the oceans and their ecological health. Publishing his ...
... A critical component of NASA,s Mars exploration program ... in-depth analysis, plans for which are detailed in ... peer-reviewed journal published by Mary Ann Liebert, Inc. ... www.liebertpub.com/ast In the published report entitled, ...
... newly developed robot capable of diving as deep ... has been successfully completed by scientists and engineers ... the University of Washington (UW). The vehicle ... for seafloor instruments that will be deployed in ...
Cached Biology News:Oceans on the precipice: Scripps scientist warns of mass extinctions and 'rise of slime' 2Oceans on the precipice: Scripps scientist warns of mass extinctions and 'rise of slime' 3Bringing Martian samples to Earth -- preparations outlined in journal Astrobiology 2Robot vehicle surveys deep sea off Pacific Northwest 2Robot vehicle surveys deep sea off Pacific Northwest 3
Mouse monoclonal [YPF19] to Yersinia pestis ( Abpromise for all tested applications)....
... extracts cytosolic proteins from mammalian ... their phosphorylation state. The reagent, ... Protein Extraction reagent, includes four ... with Western blotting, immunoprecipitations, and ...
... The features we add to WinList ... the product every day. Features like automatic ... are the result of good suggestions, thoughtful ... of the features you depend on are ...
Ubiquitin-like protein 4A (Ubiquitin-like protein GDX). [Source:Uniprot/SWISSPROT;Acc:P11441] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Biology Products: